GlassScriptPhysician profile
Deborah Dobson Moore
NPI 1437131257
$11,645.87
in general payments reported to CMS, 2019-2025
23 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,146 · 2022: $2,969 · 2023: $2,497 · 2024: $2,625 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,100 · Education: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,100.38 |
| Education | $429.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,389.44 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,570.93 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,040.55 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,028.53 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $914.04 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $729.65 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $644.89 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $562.06 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $547.73 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Sunovion Pharmaceuticals INC. | $343.52 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $169.37 | 2024-2025 | Cobenfy |
| Abbott Laboratories | $150.80 | 2023 | Freestyle Libre 3 |
| Indivior INC. | $129.65 | 2022-2024 | Perseris |
| Lundbeck LLC | $122.78 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $75.51 | 2022-2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $65.68 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $38.59 | 2021-2022 | |
| Allergan, INC. | $29.99 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.00 | 2023 | |
| Corium, LLC | $22.61 | 2021 | |
| Tris Pharma INC | $15.28 | 2025 | Dyanavel Xr |
| Almatica Pharma LLC | $14.15 | 2024 | Loreev Xr |
| Eisai INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.